

PRESS RELEASE

September 29th, 2020

ChloraSolv is awarded by Region Skåne

RLS Global is pleased to inform about the acceptance of ChloraSolv by Region Skåne. ChloraSolv is available as of today, September 29th. This is the result of positive clinical evaluations from both acute- and primary care and it is an important milestone for RLS as Region Skåne is one of the largest regions in Sweden with about 1,4 million inhabitants.

RLS works systematically with the regions on the Swedish market with the aim of getting ChloraSolv on tender agreements. The pandemic impact has made the processes longer, but now the procurement departments are starting to open for a dialogue and decision making.

ChloraSolv is awarded on contract in three regions. There is a strong interest in the product, and above all, the primary care sector finds this technology an important complement in the treatment of chronic wounds.

In Region Kalmar, we have repeated orders. In the Stockholm Region, the launch has started and RLS is now educating the care givers about ChloraSolv and the first orders are delivered.

"We are happy that the healthcare sector is gradually starting to open up, and we can conduct our negotiations with the regions. The results from the Region Skåne have been very good and is the reason why we have been awarded in the region says Karin Fischer, CEO of RLS Global. Sweden is our home market and has the highest priority in our global launch. It is therefore satisfying that more regions are choosing to include ChloraSolv on agreements, Karin Fischer concludes".

Contact information

Karin Fischer, CEO

E-mail: karin.fischer@rlsglobal.se

Telephone: +46 702 48 46 51

Anders Husmark, CBDO RLS Global AB

E-mail: anders.husmark@rlsglobal.se

Telefon: +46 724 50 94 03

Trading place and certified advisor

RLS Global's shares has been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Advisor is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012 - 2017, the company was listed on Aktietorget.

About RLS Global AB

RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North Growth Market. Certified Advisor is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se Read more at www.rls.global